Innovent Signs US$1.1B Licensing Alliance with Spero for IBI355 (SP001), for the Teatment Immune-Mediated Diseases
By Naini Anand
Pharma Deals Review: Vol 2026 Issue 8 (Table of Contents)
Published: 5 Aug-2026
DOI: 10.3833/pdr.v2026.i8.3031 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Innovent Biologics and Spero Therapeutics have entered into a global license agreement for IBI355 (SP001), a third-generation Fc-silent anti-CD40L antibody...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
PharmaDeals will be moved to a new platform by October 31, 2026. Please look out for an email from your IQVIA account manager by the end of September with details.
RSS